Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
This sub-city level research showcases that vaccine use varies substantially even within cities and that urban policies are important for ensuring equitable access to adult vaccines. Demographic factors that vary within cities can also impact vaccination coverage, and accounting for these factors will be important for achieving equity of vaccine use. Optimal use of adult vaccines can be potentially enhanced with a focus on tracking adult vaccination data regularly at national and sub-national levels, ensuring financial considerations do not impact vaccine uptake, increasing the number of vaccinators, ensuring that vaccine policies account for sub-city level differences in vaccine use, and providing the basis for a growing and robust market that has incentives for ongoing innovation.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.